In vitro, FGF15/19 intervention attenuated PA‐induced metabolic disorders and lipid accumulation in mouse atrial cardiomyocytes coupled with increased inflammation and the phosphorylation of CaMKII and YAP, which was reversed by the PPARα inhibitor. Here, CAMK2G is linked to metabolic disease.